Thursday, November 19, 2015

Watch Patients Treated For Hepatitis C: Studying possible regression in cirrhosis/ fibrosis

Q&A With Ana Maria Crissien From Scripps Green Hospital: Studying Regression In Liver Disease
Conference Coverage > AASLD 2015
Nov 19, 2015 | Adam Hochron
A considerable amount of research has been done looking at how liver disease can progress in patients, but a recent study looked at possible regression in conditions like cirrhosis and fibrosis. Ana Maria Crissien, MD, from the Scripps Green Hospital in California discussed the results of this research during the annual Liver Meeting in San Francisco.

2015 Liver Meeting | AASLD 2015

Q&A with Barry Schlansky, MD, from Oregon Health & Science University: Taking a New Look at Liver Transplants for Obese Patients VIDEO
Nov 18, 2015 | AASLD 2015 | Adam Hochron
In the past, patients deemed obese (especially those who were morbidly obese) may have been passed over for a life-saving liver transplant. A recent study showed they may be just as viable candidates for the procedure as others in the patient population.

Should Obese Patients Get Liver Transplants?
Nov 18, 2015 | AASLD 2015 | Gale Scott
Obese people are generally less healthy than those of normal weight, but that should not be a barrier to liver transplantation, researchers said at the 2015 Liver Meeting (AASLD) in San Francisco, CA.

Nations Awaiting Price Break in HCV Drugs
Nov 18, 2015 | AASLD 2015 | Gale Scott
Price is still the main obstacle in getting hepatitis C direct-acting antivirals to nations that need them, panelists agreed at a "global challenges" forum at the 2015 Liver Meeting in San Francisco, CA.

Who Gets a Liver? Transplant Centers Differ on Substance Abuse Abstinence Rules
Nov 17, 2015 | AASLD 2015 | Gale Scott
Donor livers are scarce, donated organs are precious, and transplant surgeons make the final call on whether to transplant. When the question of whether to give a liver to a patient who uses marijuana, drinks too much alcohol, or even smokes tobacco comes up, the issue gets tricky.

HCV: Making it Rare in the US Will Cost $106 Billion, Study Finds
Nov 17, 2015 | AASLD 2015 | Gale Scott
The annual US cost of HCV treatment before direct-acting antivirals was $7 billion and since then it has grown to $21 billion, but that cost should drop when generics arrive, to $14 million annually by 2030. Making it a rare disease over the next 25 years will take $106 billion, researchers project.

Vitamin E Looks Promising, Safe, for Liver Disease
Nov 17, 2015 | AASLD 2015 | Gale Scott
Researchers see promise in vitamin E treatment for NASH.

Coverage starts here.....

No comments:

Post a Comment